ALSERES PHARMACEUTICALS, INC.
|ALSERES PHARMACEUTICALS, INC. Patent applications|
|Patent application number||Title||Published|
|20090297446||LABELED IODINATED TROPANE FORMULATION - A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [||12-03-2009|
|20090252712||CHIMERIC C3-LIKE RHO ANTAGONIST BONE THERAPEUTIC - Methods of treating bone disorders in a subject in need thereof by administering to said subject a therapeutically effective amount of a Rho antagonist are disclosed.||10-08-2009|
|20090221521||SYSTEMIC PURINE ADMINISTRATION: MODULATING AXONAL OUTGROWTH OF CENTRAL NERVOUS SYSTEM NEURONS - Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The methods are noted for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, traumatic brain injury, cerebral aneurism, spinal cord injury and the like).||09-03-2009|
|20090156491||METHODS OF INHIBITING ANGIOGENESIS WITH FRAGMENTS AND HOMOLOGS OF TROPONIN SUBUNIT I - The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I.||06-18-2009|
Patent applications by ALSERES PHARMACEUTICALS, INC.